Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 385

3.
5.

Multifunctional role of VIP in prostate cancer progression in a xenograft model: suppression by curcumin and COX-2 inhibitor NS-398.

Fernández-Martínez AB, Bajo AM, Valdehita A, Isabel Arenas M, Sánchez-Chapado M, Carmena MJ, Prieto JC.

Peptides. 2009 Dec;30(12):2357-64. doi: 10.1016/j.peptides.2009.09.018. Epub 2009 Sep 20.

PMID:
19772879
6.

Therapeutic efficacy of curcumin/TRAIL combination regimen for hormone-refractory prostate cancer.

Andrzejewski T, Deeb D, Gao X, Danyluk A, Arbab AS, Dulchavsky SA, Gautam SC.

Oncol Res. 2008;17(6):257-67.

PMID:
19192720
7.
8.

Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer.

Kaseb AO, Chinnakannu K, Chen D, Sivanandam A, Tejwani S, Menon M, Dou QP, Reddy GP.

Cancer Res. 2007 Aug 15;67(16):7782-8.

10.
11.
12.
13.
15.

The ceramide analog, B13, induces apoptosis in prostate cancer cell lines and inhibits tumor growth in prostate cancer xenografts.

Samsel L, Zaidel G, Drumgoole HM, Jelovac D, Drachenberg C, Rhee JG, Brodie AM, Bielawska A, Smyth MJ.

Prostate. 2004 Mar 1;58(4):382-93.

PMID:
14968439
16.
17.

Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway.

Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Armaiz-Pena GN, Kamat AA, Spannuth WA, Gershenson DM, Lutgendorf SK, Aggarwal BB, Sood AK.

Clin Cancer Res. 2007 Jun 1;13(11):3423-30.

19.
20.

Combined inhibitory effects of curcumin and phenethyl isothiocyanate on the growth of human PC-3 prostate xenografts in immunodeficient mice.

Khor TO, Keum YS, Lin W, Kim JH, Hu R, Shen G, Xu C, Gopalakrishnan A, Reddy B, Zheng X, Conney AH, Kong AN.

Cancer Res. 2006 Jan 15;66(2):613-21.

Items per page

Supplemental Content

Write to the Help Desk